How are companies distinguishing between “moonshot” automation and validated digital tools that can be deployed today?
Industry leaders are drawing a clear line between "moonshot" automation — autonomous, end-to-end systems with high regulatory ambiguity — and validated digital tools that augment human decision-making within existing compliance frameworks. Youngpil Cha of Samsung Biologics explains that while conventional automation replaces standardized manual tasks with human oversight, moonshot automation aims for systems that design and execute actions autonomously, with human intervention reserved only for exceptions.
Read the full roundtable on Pharma's Almanac to explore how leading biopharma organizations are balancing near-term digital transformation with long-term innovation strategies.
Industry leaders are drawing a clear line between "moonshot" automation — autonomous, end-to-end systems with high regulatory ambiguity — and validated digital tools that augment human decision-making within existing compliance frameworks. Youngpil Cha of Samsung Biologics explains that while conventional automation replaces standardized manual tasks with human oversight, moonshot automation aims for systems that design and execute actions autonomously, with human intervention reserved only for exceptions.
Read the full roundtable on Pharma's Almanac to explore how leading biopharma organizations are balancing near-term digital transformation with long-term innovation strategies.
Share article
Related Content